# TODO

## üìä **HIGH PRIORITY QUEUE**

---



- New Function: advancedcompetingrisks.b.R
- Key Features:
  - Gray's test for comparing cumulative incidence
  - Subdistribution hazard ratios
  - Time-dependent cumulative incidence plots
  - Risk stratification for competing events

  1.2 Cure Models Implementation

  Target Package: smcure (add to dependencies)

- New Function: curemodels.b.R
- Key Features:
  - Mixture cure models
  - Non-mixture cure models
  - Cure fraction estimation
  - Long-term survivor identification

  1.3 Multistate Survival Models

  Target Package: mstate (add to dependencies)

- New Function: multistatesurvival.b.R
- Key Features:
  - Transition probability matrices
  - Multi-state Kaplan-Meier
  - Disease progression modeling
  - Treatment response pathways

  üéØ Phase 2: Advanced Clinical Analytics (High Priority)

  2.1 Relative Survival Analysis

  Target Package: relsurv (add to dependencies)

- New Function: relativesurvival.b.R
- Key Features:
  - Excess mortality modeling
  - Population-based survival comparisons
  - Cancer registry analysis
  - Age-standardized survival rates

  2.2 Enhanced Model Validation

  Target Package: pec (add to dependencies)

- New Function: survivalvalidation.b.R
- Key Features:
  - Prediction error curves
  - Cross-validation for survival models
  - Model comparison metrics
  - Calibration plots

  2.3 Joint Longitudinal-Survival Modeling

  Target Packages: JMbayes, joineR (add to dependencies)

- New Function: jointmodeling.b.R
- Key Features:
  - Longitudinal biomarker integration
  - Dynamic predictions
  - Time-varying covariates
  - Bayesian estimation

  üìä Phase 3: Specialized Applications (Medium Priority)

  3.1 Machine Learning Enhancement

  Target Packages: Enhance existing randomForestSRC, glmnet

- Enhanced Function: Update multisurvival.b.R
- Key Features:
  - Cross-validated feature selection
  - Ensemble methods
  - Variable importance plots
  - Prediction intervals

  3.2 Parametric Survival Models

  Target Package: Enhance existing flexsurv

- Enhanced Function: Update survival.b.R
- Key Features:
  - Spline-based hazard functions
  - Parametric regression
  - Model diagnostics
  - Extrapolation capabilities

  3.3 Bayesian Survival Analysis

  Target Package: rstanarm (add to dependencies)

- New Function: bayesiansurvival.b.R
- Key Features:
  - Posterior inference
  - Uncertainty quantification
  - Hierarchical modeling
  - Prior specification

  üîß Technical Implementation Specifications

  A. New Dependencies to Add (DESCRIPTION file):

  Imports:
    smcure,      # Cure models
    mstate,      # Multistate models  
    relsurv,     # Relative survival
    pec,         # Model validation
    JMbayes,     # Joint modeling
    joineR,      # Joint modeling alternative
    rstanarm,    # Bayesian methods
    prodlim,     # Fast algorithms
    survAUC      # Additional validation

  B. New Jamovi Module Structure:

  jamovi/
  ‚îú‚îÄ‚îÄ curemodels.a.yaml           # Cure model analysis
  ‚îú‚îÄ‚îÄ multistatesurvival.a.yaml   # Disease progression modeling
  ‚îú‚îÄ‚îÄ relativesurvival.a.yaml     # Population-based survival
  ‚îú‚îÄ‚îÄ survivalvalidation.a.yaml   # Model validation
  ‚îú‚îÄ‚îÄ jointmodeling.a.yaml        # Longitudinal-survival integration
  ‚îî‚îÄ‚îÄ bayesiansurvival.a.yaml     # Bayesian survival analysis

  R/
  ‚îú‚îÄ‚îÄ curemodels.b.R              # Implementation files
  ‚îú‚îÄ‚îÄ multistatesurvival.b.R
  ‚îú‚îÄ‚îÄ relativesurvival.b.R
  ‚îú‚îÄ‚îÄ survivalvalidation.b.R
  ‚îú‚îÄ‚îÄ jointmodeling.b.R
  ‚îî‚îÄ‚îÄ bayesiansurvival.b.R

  C. Enhanced Existing Functions:

- survival.b.R: Add cure model options, enhanced residuals
- multisurvival.b.R: Integrate ensemble ML methods, Bayesian options
- competingsurvival.b.R: Enhanced cumulative incidence, Gray's test



---

# Stage Migration Module - Future Enhancements



## **Phase 4: Enhanced Features from ChatGPT Stage Migration Analysis**

### **1. Advanced Will Rogers Phenomenon Analysis**

- **Temporal Comparison Framework:** Compare stage-specific survival across different time periods to detect artifacts vs. real improvements

### **2. Real-World Clinical Examples Integration**

- **Cancer-Specific Templates:**
  - Pancreatic cancer AJCC 8th edition validation templates
  - Colorectal cancer lymph node examination effects
  - Thyroid cancer age threshold migration analysis
  - Lung cancer imaging advancement effects
- **Era Comparison Tools:** Temporal analysis accounting for diagnostic advancement bias
- **Morphologic Feature Integration:** Tools for adding new prognostic factors (size, invasion patterns, etc.)

### **3. Methodological Validation Framework**

- **External Validation Tools:** Framework for validating staging systems on independent cohorts
- **Sensitivity Analysis:** Robust analysis under different assumptions and scenarios

### **4. Clinical Decision Support Enhancements**

- **Cost-Effectiveness Considerations:** Framework for evaluating staging system implementation costs

---

## **Phase 5: Advanced Features from Claude Stage Migration Analysis**

### **1. Advanced Cox Modeling Enhancements**

- ‚úÖ **Frailty Models for Clustering:** Mixed-effects Cox models (coxme) for multi-institutional data with center-specific random effects (v0.0.3.81)

### **2. Enhanced Stage Migration Quantification**

- **Migration Correction Methods:** Apply probability-weighted expectations to adjust for migration effects

### **3. Regulatory and Clinical Guidelines Integration**

- **REMARK Guidelines Adherence:** 20-item checklist for prognostic marker studies
- **TRIPOD Statement Compliance:** 27-item checklist for prediction model development
- **Registry Compatibility Assessment:** Ensure new staging aligns with cancer registry systems
- **Timeline Projection Tools:** Estimate development-validation-implementation timeline (5-7 years)

### **4. Advanced Validation Methodologies**

- **Transportability Assessment:** Evaluate performance across different populations and settings
- **Temporal Validation:** Assess performance on data from different time periods
- **Geographic Validation:** Test staging system across different geographic regions

### **5. Enhanced Discrimination Metrics**

- ‚úÖ **Concordance Probability Estimates:** Alternative concordance measures for heavily censored data (v0.0.3.80)
- ‚úÖ **Win Ratio Analysis:** Composite endpoint analysis for staging comparison (v0.0.3.80)

### **6. Clinical Decision Analysis Integration**

- **Clinical Utility Index:** Combine sensitivity/specificity with disease prevalence
- **Number Needed to Treat:** Calculate NNT based on staging-guided interventions

### **7. Machine Learning Integration**

- **Deep Learning Survival Models:** Neural network approaches for complex interactions
- **Ensemble Methods:** Combine multiple models for robust predictions
- **Feature Importance Analysis:** SHAP values and permutation importance
- **Cross-Validation for ML:** Proper CV strategies for survival ML models

### **8. Reporting and Visualization Excellence**

- **CONSORT-Style Flow Diagrams:** Patient flow through staging analysis
- **Calibration Belt Plots:** Advanced calibration visualization with confidence regions
- **Nomogram Generation:** Clinical prediction tools from staging models
- **Interactive Web Reports:** Shiny-based interactive staging comparison dashboards

### **9. Sample Size and Power Analysis**

- **Multi-Stage Power Analysis:** Power calculations for hierarchical staging comparisons
- **Simulation-Based Power:** Monte Carlo methods for complex staging scenarios
- **Adaptive Sample Size:** Interim analysis and sample size re-estimation

### **10. Biomarker Integration Framework**

- **Multi-Marker Panels:** Combine multiple biomarkers with anatomic staging
- **Cost-Effectiveness Analysis:** Evaluate biomarker addition from economic perspective
- **Missing Biomarker Handling:** Multiple imputation for incomplete biomarker data
- **Validation of Biomarker Staging:** Specific validation approaches for integrated staging

---

## **Phase 6: Advanced Features from Gemini Stage Migration Analysis**

### **1. Systematic Stage Development Framework**

- **Bootstrap Model/Cutpoint Selection Method:** Systematic search across candidate staging systems using bootstrap-estimated criteria
- **Orderly Progressive Condensation:** Define T and N category groupings with partial ordering constraints
- **Minimum Stage Size Constraints:** Ensure each stage contains ‚â•5% of sample for statistical stability
- **Eligible System Generation:** Algorithm to generate all valid candidate staging systems adhering to pre-specified rules

### **2. Advanced Multi-cutpoint Optimization**

- **Simultaneous Optimization:** Multiple cutpoint optimization for complex staging systems

### **3. Model Interpretability Enhancement**

- **SHAP Summary Plots:** Visualize direction and magnitude of feature impacts across dataset
- **SHAP Bar Plots:** Rank features by average absolute SHAP values for importance hierarchy
- **SHAP Dependence Plots:** Reveal non-linear relationships and feature interactions
- **Individual Force Plots:** Patient-specific prediction explanations showing feature contributions
- **Global vs Local Interpretability:** Framework for both population-level and individual-level explanations

### **4. Stage Migration Quantification Tools**

- **Immune Response Hypothesis Testing:** Assess if lymph node count reflects immune response vs. understaging
- **Lymph Node Yield Analysis:** Correlate node count with survival independent of positivity
- **Temporal Migration Tracking:** Monitor stage distribution changes over diagnostic eras
- **Multi-Factor Migration Analysis:** Separate effects of diagnostic improvement vs. biological factors

### **5. Clinical Implementation Framework**

- **Online Platform Deployment:** Web calculator implementation for real-time risk assessment
- **Electronic Health Record Integration:** Embed staging tools within clinical workflows
- **Clinical Workflow Optimization:** Streamline staging assessment at point of care

### **6. Advanced Performance Metrics Implementation**

- **Landmark Analysis Framework:** Convert survival to binary outcomes at clinically relevant timepoints
- **Explained Variation (œÄÃÇ):** Landmark-based measure of prognostic power
- **Concordance Probability (KÃÇ):** Generalized C-index accounting for all observation pairs

### **7. R Package Integration Suite**

- **SurvMetrics Integration:** Enhanced C-index calculations for tied survival data
- **calibmsm for Multistate Models:** Advanced calibration assessment for complex transitions

### **8. Biomarker and Additional Factor Integration**

- **Inflammation-Based Biomarkers:** NAR, SII, PNI integration into staging
- **Pathology Grade Integration:** Incorporate tumor differentiation into staging
- **Molecular Alterations:** BRAF mutations, tumor markers (CEA) as staging factors
- **Treatment Response Factors:** Surgery status, adjuvant therapy considerations
- **Comorbidity Adjustment:** Account for patient factors affecting prognosis

### **9. Quality Assurance and Regulatory Compliance**

- **Missing Data Pattern Analysis:** Identify and handle systematic missingness
- **Cancer-Specific Validation:** Tailored approaches for different malignancy types

### **10. Advanced Visualization Suite**

- **Interactive Dashboard Components:** Dynamic visualizations for exploring results

### **11. Clinical Translation Tools**

- **Implementation Timelines:** Project 5-7 year development-validation-adoption cycle
- **Training Module Development:** Educational resources for new staging criteria
- **Performance Monitoring Framework:** Track real-world staging system performance

---

## **Next Priority Features**

Based on current implementation status, the next logical features to implement would be:

1. **Deep Learning Survival Models** (Phase 5, Section 7) - Neural network approaches for complex interactions and ensemble methods
2. **Clinical Utility Index** (Phase 5, Section 6) - Combine sensitivity/specificity with disease prevalence for clinical decision analysis
3. **Migration Correction Methods** (Phase 5, Section 2) - Apply probability-weighted expectations to adjust for migration effects
4. **Multi-level Staging Creation** (Phase 6, Section 4) - Simultaneous multi-cutpoint optimization for complex staging systems

These represent the most methodologically sound next steps that build upon the existing advanced survival analysis foundation.

---

# CRAN Task Views Implementation Plan for ClinicoPath Enhancement

## Executive Summary

Based on comprehensive analysis of CRAN Task Views, this implementation plan prioritizes 16 key Task Views that will significantly enhance ClinicoPath's capabilities for clinical and pathological research. The plan is organized into 4 phases over 18-24 months, focusing on maximum clinical impact and user value.

## Phase 1: Core Clinical Research Tools (Months 1-6)

### üöÄ Priority 1: Clinical Trials Task View Integration

**Target Package Suite:** `PowerTOST`, `TrialSize`, `gsDesign`, `pwr`, `Hmisc`

#### New Functions to Implement

**1. Clinical Trial Designer (`clinicaltrialdesign.b.R`)**

- Sample size calculations for superiority/non-inferiority/equivalence trials
- Power analysis for biomarker studies
- Group sequential design with interim analysis
- Adaptive sample size re-estimation
- Randomization procedures with stratification
- Bayesian adaptive designs

**2. Sample Size Calculator (`samplesizecalc.b.R`)**

- Two-sample t-tests, chi-square tests
- Survival analysis (log-rank test) power calculations
- Diagnostic test accuracy studies
- Correlation and regression analysis
- Multiple testing correction considerations

**Implementation Details:**

```yaml
# jamovi/clinicaltrialdesign.a.yaml
name: clinicaltrialdesign
title: Clinical Trial Design and Power Analysis
menuGroup: Clinical Research
menuSubgroup: Study Design
```

**Clinical Impact:** Essential for proper study planning, reducing underpowered studies, optimizing resource allocation.

---

### üéØ Priority 2: Meta-Analysis Task View Integration

**Target Package Suite:** `metafor`, `meta`, `netmeta`, `mada`, `bayesmeta`

#### New Functions to Implement

**1. Diagnostic Test Meta-Analysis (`diagnosticmeta.b.R`)**

- Bivariate random-effects model for sensitivity/specificity
- HSROC (Hierarchical Summary ROC) curves
- Publication bias assessment (funnel plots, Egger's test)
- Heterogeneity assessment (I¬≤ statistics, Q-test)
- Meta-regression for exploring heterogeneity sources

**2. Treatment Effect Meta-Analysis (`treatmentmeta.b.R`)**

- Fixed and random effects models
- Forest plots with subgroup analysis
- Network meta-analysis for multiple treatment comparisons
- Bayesian meta-analysis with informative priors
- Leave-one-out sensitivity analysis

**3. Biomarker Meta-Analysis (`biomarkermeta.b.R`)**

- Hazard ratio meta-analysis from survival studies
- Prognostic factor meta-analysis
- Individual participant data (IPD) meta-analysis framework
- Time-to-event outcome synthesis

**Implementation Details:**

```yaml
# jamovi/diagnosticmeta.a.yaml
name: diagnosticmeta
title: Diagnostic Test Accuracy Meta-Analysis
menuGroup: Meta-Analysis
menuSubgroup: Clinical Evidence Synthesis
```

**Clinical Impact:** Evidence synthesis for clinical guidelines, systematic reviews, diagnostic test evaluation.

---

### üìä Priority 3: Missing Data Task View Integration

**Target Package Suite:** `mice`, `VIM`, `naniar`, `missMethods`, `JointAI`

#### New Functions to Implement

**1. Missing Data Explorer (`missingdataexplorer.b.R`)**

- Missing data pattern visualization
- Little's MCAR test
- Missing data mechanism assessment
- Variable correlation with missingness
- Impact assessment of missing data on analyses

**2. Advanced Imputation (`advancedimputation.b.R`)**

- Multiple imputation by chained equations (MICE)
- Joint modeling imputation
- Predictive mean matching
- Bootstrap-based imputation
- Imputation diagnostics and convergence assessment

**3. Sensitivity Analysis for Missing Data (`missingsensitivity.b.R`)**

- Pattern-mixture models
- Selection models
- Tipping point analysis
- Multiple imputation sensitivity analysis

**Implementation Details:**

```yaml
# jamovi/missingdataexplorer.a.yaml
name: missingdataexplorer
title: Missing Data Analysis and Imputation
menuGroup: Data Quality
menuSubgroup: Missing Data Management
```

**Clinical Impact:** Robust handling of incomplete clinical datasets, improved validity of research findings.

---

## Phase 2: Advanced Analytics Integration (Months 7-12)

### üß† Priority 5: Machine Learning Task View Enhancement

**Target Package Suite:** `randomForest`, `xgboost`, `glmnet`, `DALEX`, `mlr3`

#### Enhanced Functions

**1. Clinical Prediction Models (`clinicalprediction.b.R`)**

- Automated feature selection pipelines
- Cross-validation with clinical considerations
- Model interpretability (SHAP, LIME)
- Prediction confidence intervals
- Clinical decision thresholds

**2. Biomarker Discovery Platform (`biomarkerdiscovery.b.R`)**

- High-dimensional data handling
- Ensemble methods for robust prediction
- Stability selection for biomarker identification
- Pathway-informed feature selection
- Multi-omics integration

**Implementation Details:**

- Enhance existing `multisurvival.b.R` and create new specialized functions
- Integration with survival analysis workflow

**Clinical Impact:** Advanced predictive modeling, biomarker discovery, personalized medicine approaches.

---

### üìà Priority 6: Psychometrics Task View Integration

**Target Package Suite:** `psych`, `lavaan`, `mirt`, `CTT`, `networktools`

#### New Functions to Implement

**1. Patient-Reported Outcomes (`patientreported.b.R`)**

- Scale reliability analysis (Cronbach's Œ±, McDonald's œâ)
- Factor analysis for construct validity
- Item response theory (IRT) analysis
- Differential item functioning (DIF) assessment
- Longitudinal measurement invariance

**2. Quality of Life Analysis (`qualityoflife.b.R`)**

- Multi-domain QoL assessment
- Clinically important difference estimation
- Responder analysis
- Time-to-deterioration analysis
- Mixed models for repeated QoL measures

**Implementation Details:**

```yaml
# jamovi/patientreported.a.yaml
name: patientreported
title: Patient-Reported Outcome Measures Analysis
menuGroup: Clinical Assessment
menuSubgroup: Patient Outcomes
```

**Clinical Impact:** Comprehensive patient outcome assessment, scale validation, clinical trial endpoints.

---

## Phase 3: Specialized Clinical Methods (Months 13-18)

### ‚öñÔ∏è Priority 7: Causal Inference Task View Integration

**Target Package Suite:** `MatchIt`, `WeightIt`, `CausalImpact`, `DoubleML`

#### New Functions to Implement

**1. Treatment Effect Estimation (`treatmenteffects.b.R`)**

- Propensity score matching and weighting
- Inverse probability of treatment weighting (IPTW)
- Doubly robust estimation
- Instrumental variable analysis
- Regression discontinuity design

**2. Observational Study Analysis (`observationalstudy.b.R`)**

- Confounding assessment and control
- Sensitivity analysis for unmeasured confounding
- E-values for robustness assessment
- Marginal structural models

**Implementation Details:**

```yaml
# jamovi/treatmenteffects.a.yaml
name: treatmenteffects
title: Causal Inference and Treatment Effects
menuGroup: Causal Analysis
menuSubgroup: Observational Studies
```

**Clinical Impact:** Robust causal inference from observational data, treatment effectiveness evaluation.

---

### üî¨ Priority 8: Epidemiology Task View Integration

**Target Package Suite:** `EpiModel`, `incidence2`, `surveillance`, `epiR`, `epitools`

#### New Functions to Implement

**1. Outbreak Analysis (`outbreakanalysis.b.R`)**

- Epidemic curve generation
- Basic and effective reproduction number (R‚ÇÄ, R‚Çë)
- Attack rate calculations
- Case-control study analysis for outbreaks
- Spatial clustering detection

**2. Screening Program Evaluation (`screeningevaluation.b.R`)**

- Test performance in screening settings
- Lead-time and length-time bias assessment
- Number needed to screen calculations
- Cost-effectiveness of screening programs
- ROC analysis for screening thresholds

**Implementation Details:**

```yaml
# jamovi/outbreakanalysis.a.yaml
name: outbreakanalysis
title: Epidemiological Analysis and Outbreak Investigation
menuGroup: Epidemiology
menuSubgroup: Disease Surveillance
```

**Clinical Impact:** Public health surveillance, outbreak investigation, screening program optimization.

---

### üé≤ Priority 9: Bayesian Task View Integration

**Target Package Suite:** `brms`, `rstanarm`, `MCMCpack`, `BayesFactor`

#### New Functions to Implement

**1. Bayesian Clinical Analysis (`bayesianclinical.b.R`)**

- Bayesian t-tests and ANOVA
- Bayesian regression with informative priors
- Hierarchical models for multi-center data
- Bayesian model averaging
- Prior sensitivity analysis

**2. Adaptive Trial Design (`adaptivetrial.b.R`)**

- Bayesian adaptive randomization
- Futility and efficacy monitoring
- Dose-finding with continual reassessment
- Predictive probability calculations
- Decision-theoretic approaches

**Implementation Details:**

```yaml
# jamovi/bayesianclinical.a.yaml
name: bayesianclinical
title: Bayesian Clinical Analysis
menuGroup: Bayesian Methods
menuSubgroup: Clinical Research
```

**Clinical Impact:** Incorporation of prior knowledge, adaptive trial designs, uncertainty quantification.

---

## Phase 4: Advanced Specialized Applications (Months 19-24)

### üîó Priority 10: Mixed Models Task View Enhancement

**Target Package Suite:** `lme4`, `nlme`, `glmmTMB`, `MCMCglmm`

#### Enhanced Functions

**1. Longitudinal Clinical Data (`longitudinalclinical.b.R`)**

- Mixed-effects models for repeated measures
- Growth curve modeling
- Time-varying covariates
- Missing data handling in longitudinal models
- Model diagnostics and visualization

**2. Multi-Center Study Analysis (`multicenterstudy.b.R`)**

- Random effects for center heterogeneity
- Fixed vs. random effects decision frameworks
- Intracluster correlation assessment
- Center-specific inference

**Clinical Impact:** Proper analysis of clustered and longitudinal clinical data, multi-center trial analysis.

---


### üìã Priority 12: Experimental Design Task View Integration

**Target Package Suite:** `DoE.base`, `FrF2`, `rsm`, `AlgDesign`

#### New Functions to Implement

**1. Laboratory Assay Optimization (`assayoptimization.b.R`)**

- Factorial design for assay conditions
- Response surface methodology
- Optimal design for parameter estimation
- Robustness testing protocols

**Clinical Impact:** Laboratory protocol optimization, assay validation, quality control.

---

## Implementation Timeline and Resource Allocation

### Development Phases

- **Phase 1 (Months 1-6):** 3 developers, focus on clinical trial tools
- **Phase 2 (Months 7-12):** 4 developers, advanced analytics team
- **Phase 3 (Months 13-18):** 3 developers, specialized methods
- **Phase 4 (Months 19-24):** 2 developers, advanced applications

### Key Milestones

- **Month 3:** Clinical trial design module release
- **Month 6:** Meta-analysis and missing data modules release
- **Month 9:** Medical imaging and ML enhancement release
- **Month 12:** Psychometrics module release
- **Month 15:** Causal inference module release
- **Month 18:** Epidemiology and Bayesian modules release
- **Month 21:** Mixed models enhancement release
- **Month 24:** Full suite integration and final release

### Success Metrics

- User adoption rates for new modules
- Citation impact in clinical literature
- Integration with clinical workflows
- User feedback and satisfaction scores
- Performance benchmarks against existing tools

### Risk Mitigation

- Parallel development tracks to avoid bottlenecks
- Regular user testing and feedback incorporation
- Compatibility testing across jamovi versions
- Documentation and training material development
- Community engagement and support

---

## Expected Clinical Impact Summary

### Immediate Impact (Phase 1)

- **50% improvement** in study design quality through proper power analysis
- **Standardized meta-analysis** capabilities for evidence synthesis
- **Robust handling** of missing data in 90% of clinical studies

### Medium-term Impact (Phases 2-3)

- **Integration** of imaging and pathology data analysis
- **Advanced predictive modeling** for clinical decision support
- **Causal inference** capabilities for observational study analysis

### Long-term Impact (Phase 4)

- **Precision medicine** applications through omics integration
- **Multi-center study** analysis standardization
- **Laboratory optimization** and quality control enhancement

This comprehensive implementation plan will position ClinicoPath as the leading clinical research analysis platform in the jamovi ecosystem, serving researchers, clinicians, and pathologists worldwide.

---

# Digital Pathology Statistical Methods Roadmap

## Executive Summary

Based on comprehensive analysis of 195 articles from the American Journal of Pathology and extensive review of statistical methods in digital pathology research, this roadmap identifies critical statistical methods currently missing from our ClinicoPath jamovi module. The analysis reveals that 93% of pathology studies employ statistical testing, with significant methodological gaps in our current implementation.

## Phase 1: Essential Classical Tests (Immediate Priority - Months 1-3)

### üö® **Critical Missing Tests - High Usage in Pathology (30%+ of studies)**

#### 1. Enhanced Non-Parametric Tests (`enhancednonparametric.b.R`)
- **Mann-Whitney U Test Enhancement** 
  - Current: Basic implementation in existing modules
  - **Missing**: Assumption checking, effect size (rank-biserial correlation), confidence intervals
  - **Usage**: ~30% of pathology studies comparing biomarker expression
  - **Priority**: CRITICAL - Most used test in digital pathology

- **Kruskal-Wallis Test with Post Hoc Analysis**
  - Current: Basic implementation
  - **Missing**: Proper post hoc testing (Dunn's test), effect sizes, pairwise comparisons
  - **Usage**: Comparing biomarker expression across tumor stages
  - **Priority**: HIGH - 68% of studies fail to perform proper post hoc testing

#### 2. Advanced ANOVA Suite (`advancedanova.b.R`)
- **ANOVA with Comprehensive Post Hoc Testing**
  - Current: Basic ANOVA available
  - **Missing**: Tukey HSD, Dunnett's test, Games-Howell, Bonferroni corrections
  - **Issue**: 68% of studies fail to perform proper multiple comparisons
  - **Priority**: CRITICAL - Prevents statistical errors in pathology research

#### 3. Enhanced Chi-Square and Fisher's Tests (`categoricaladvanced.b.R`)
- **Chi-Square Test Enhancement**
  - Current: Basic implementation
  - **Missing**: Effect sizes (Cram√©r's V, phi coefficient), residual analysis, goodness-of-fit tests
- **Fisher's Exact Test Enhancement**
  - Current: Available in crosstable
  - **Missing**: Odds ratio confidence intervals, stratified analysis
  - **Usage**: Biomarker positivity vs. survival status analysis

## Phase 2: Spatial Statistics for Digital Pathology (Months 4-8)

### üî¨ **Critical Missing Capability - Unique to Digital Pathology**

#### 4. Spatial Point Pattern Analysis (`spatialpathology.b.R`)
**Target Packages**: `spatstat`, `spatialTIME`, `SpatialQPFs`

- **Ripley's K Function Analysis**
  - Mathematical basis: K(r) = Œª‚Åª¬πE[number of points within distance r]
  - L-function transformation for easier interpretation
  - Critical for immune cell clustering analysis
  - **Usage**: Essential for multiplex immunofluorescence analysis

- **Morisita Index for Clustering**
  - Immune cell clustering detection
  - Spatial randomness testing
  - **Application**: Tumor immune microenvironment analysis

- **Getis-Ord Gi* Statistics**
  - Hotspot detection for biomarker expression
  - Local spatial autocorrelation
  - **Application**: Identifying areas of high biomarker activity

#### 5. Multi-Type Spatial Analysis (`multiTypeParial.b.R`)
- **Cross-Type K Functions**
  - Analyzing relationships between different cell types
  - Distance-based interaction analysis
- **Clark-Evans Nearest Neighbor Analysis**
  - Spatial distribution pattern assessment
- **Integration**: High compatibility with `spatialTIME` package (CRAN)

## Phase 3: Hierarchical Data Analysis (Months 6-10)

### üìä **Critical for WSI and ROI Analysis**

#### 6. Advanced Mixed-Effects Models (`hierarchicalpathology.b.R`)
**Target Packages**: `lme4`, `nlme`, `performance`

- **Three-Level Hierarchical Models**
  - Structure: Patient > Slide > ROI > Cell
  - Random effects for multiple levels of clustering
  - **Current Gap**: No support for complex nested pathology data

- **Variance Component Analysis**
  - Intraclass Correlation Coefficient (ICC) calculation
  - Partition variance across hierarchical levels
  - **Application**: Multi-ROI and multi-slide analysis reliability

- **Generalized Linear Mixed Models (GLMMs)**
  - Logistic mixed models for binary outcomes
  - Poisson mixed models for cell count data
  - **Application**: Cell count analysis with nested structure

## Phase 4: Advanced Survival Analysis for Biomarkers (Months 9-12)

### ‚è±Ô∏è **Enhanced Survival Methods**

#### 7. Optimal Cutpoint Determination (`optimalcutpoint.b.R`)
**Target Packages**: `survminer`, `maxstat`

- **Maximally Selected Rank Statistics**
  - Optimal cutpoint for continuous biomarkers
  - Multiple biomarker optimization
  - **Current Gap**: Basic cutpoint methods only

- **Concordance Index Optimization**
  - C-index based cutpoint selection
  - Time-dependent ROC analysis
  - **Application**: Nuclear morphometry and texture analysis cutpoints

#### 8. Time-Dependent ROC Analysis (`timedependentroc.b.R`)
**Target Packages**: `timeROC`, `survivalROC`, `survAUC`

- **Dynamic ROC Curves**
  - Cumulative/Dynamic (C/D) approaches
  - Incident/Dynamic (I/D) approaches
  - **Application**: Evaluating biomarker discrimination over time

## Phase 5: Cell Segmentation and Count Analysis (Months 10-14)

### üß¨ **Specialized for Digital Pathology Data**

#### 9. Count Data Models (`countanalysis.b.R`)
**Target Packages**: `MASS`, `pscl`, `glmmTMB`

- **Zero-Inflated Models**
  - Zero-inflation Poisson (ZIP)
  - Zero-inflation Negative Binomial (ZINB)
  - **Application**: Cell count data with excess zeros

- **Tabular Morphometry Analysis**
  - Statistical analysis of pre-extracted shape measurements
  - Distribution analysis of morphometric features
  - **Note**: Requires features to be extracted externally and imported as tabular data

#### 10. Algorithm Performance Metrics (`algorithmmetrics.b.R`)
**Note**: Works with pre-calculated validation metrics in tabular format

- **Statistical Analysis of Validation Metrics**
  - Analysis of Dice coefficients across samples
  - Statistical comparison of algorithm performances
  - Agreement statistics between methods
  - **Application**: Statistical validation of pre-computed metrics

## Phase 6: Inter-Observer Agreement (Months 12-16)

### ü§ù **Critical for Pathology Validation**

#### 11. Advanced Agreement Statistics (`pathologyagreement.b.R`)
**Target Packages**: `psych`, `irr`, `blandr`

- **Enhanced Kappa Statistics**
  - Cohen's Œ∫ for two-rater agreement
  - Fleiss' Œ∫ for multiple raters
  - Weighted kappa for ordinal data
  - **Interpretation**: Œ∫ > 0.61 indicates substantial agreement

- **Intraclass Correlation Coefficient (ICC)**
  - ICC(1,1), ICC(2,1), ICC(3,1) for different study designs
  - **Interpretation**: ICC > 0.75 indicates good reliability
  - **Application**: Digital pathology measurement reliability

- **Bland-Altman Analysis**
  - Continuous measurement agreement
  - Bias and limits of agreement
  - **Application**: Automated vs. manual measurement comparison

## Phase 7: Machine Learning Evaluation (Months 14-18)

### ü§ñ **Pathology-Specific ML Metrics**

#### 12. Advanced ML Evaluation (`mlpathology.b.R`)
**Target Packages**: `caret`, `MLmetrics`, `DALEX`

- **Imbalanced Dataset Metrics**
  - Area Under Precision-Recall Curve (AUPRC)
  - Matthews Correlation Coefficient (MCC)
  - Balanced accuracy, G-mean: ‚àö(Sensitivity √ó Specificity)
  - **Application**: Rare disease detection, minority class analysis

- **Segmentation-Specific Metrics**
  - Enhanced Dice coefficient analysis
  - Average surface distance
  - **Application**: Cell and tissue segmentation validation

## Phase 8: Multiple Testing Corrections (Months 16-20)

### üìà **Advanced FDR Control**

#### 13. Advanced Multiple Testing (`multipletesting.b.R`)
**Target Packages**: `qvalue` (Bioconductor), `IHW`

- **Advanced FDR Methods**
  - Storey's q-value method
  - Independent Hypothesis Weighting (IHW)
  - AdaPT: Adaptive p-value thresholding
  - **Current Gap**: Only basic Bonferroni and BH-FDR available

- **Permutation-Based FDR**
  - For correlated features in high-dimensional data
  - **Application**: Multi-biomarker analysis with correlation

## Implementation Priority Matrix

### Immediate Implementation (Months 1-6)
1. **üî• NEXT: Advanced ANOVA Suite** - CRITICAL (68% need proper post hoc)
2. **‚úÖ COMPLETED: Enhanced Non-Parametric Tests** - CRITICAL (30% usage rate)
3. **‚úÖ COMPLETED: Spatial Point Pattern Analysis** - HIGH (unique to digital pathology)

### High Priority (Months 4-12)
4. **Hierarchical Mixed-Effects Models** - HIGH (WSI/ROI structure)
5. **Optimal Cutpoint Determination** - HIGH (biomarker analysis)
6. **Count Data Models** - HIGH (cell counting applications)

### Medium Priority (Months 10-18)
7. **Time-Dependent ROC Analysis** - MEDIUM (advanced survival)
8. **Segmentation Quality Metrics** - MEDIUM (validation needs)
9. **Advanced Agreement Statistics** - MEDIUM (reliability assessment)

### Future Enhancements (Months 16-24)
10. **Advanced ML Evaluation** - FUTURE (specialized metrics)
11. **Advanced Multiple Testing** - FUTURE (high-dimensional data)

## Integration with Existing ClinicoPath Modules

### Enhance Existing Functions
- **survival.b.R**: Add optimal cutpoint methods, time-dependent ROC
- **crosstable.b.R**: Enhanced chi-square with effect sizes and residuals
- **ihcstats.b.R**: Integration with spatial analysis for H-score spatial patterns

### New Module Categories
- **Spatial Analysis**: New menuGroup for spatial pathology methods
- **Digital Pathology**: Specialized menuGroup for DP-specific methods
- **Advanced Agreement**: Enhanced reliability and agreement assessment

## Expected Impact

### Research Quality Improvement
- **50% reduction** in methodological errors through proper post hoc testing
- **Standardized spatial analysis** for immune microenvironment studies
- **Robust hierarchical analysis** for multi-ROI and multi-slide studies

### Clinical Translation
- **Improved biomarker validation** through optimal cutpoint methods
- **Enhanced reproducibility** through advanced agreement statistics
- **Better segmentation validation** through comprehensive metrics

### User Adoption
- **Target**: 75% of digital pathology researchers using spatial analysis tools
- **Goal**: ClinicoPath becomes standard for digital pathology statistical analysis
- **Timeline**: 24-month implementation for complete digital pathology suite

This roadmap positions ClinicoPath as the definitive statistical analysis platform for digital pathology research, addressing the specific needs identified in peer-reviewed literature and filling critical gaps in current methodology.

---

# Digital Pathology Statistical Methods Integration Roadmap (NEW)

## Executive Summary

Based on comprehensive analysis of digital pathology research methods, this roadmap outlines the integration of essential statistical tests and analyses specifically designed for digital pathology workflows into the ClinicoPath jamovi module.

## Phase 1: Core Digital Pathology Statistics (Months 1-4)


## Phase 2: Image-Derived Metrics Analysis (Months 5-8)


### üìà **4. Classification Performance Metrics** (`mlpathology`)
**Target Packages**: `pROC`, `MLmetrics`, `caret`

#### New Functions:
- **classification_metrics.b.R**
  - Confusion matrix with comprehensive metrics
  - F1-score, precision, recall, AUROC calculation
  - McNemar's test for paired classifier comparison
  - DeLong's test for ROC curve comparison
  - Bootstrap confidence intervals for metrics

- **segmentation_metrics.b.R**
  - Dice similarity coefficient (DSC)
  - Jaccard index (IoU)
  - Hausdorff distance
  - Surface distance metrics
  - Statistical testing for segmentation comparisons

**Applications**:
- AI model validation
- Algorithm comparison studies
- Segmentation quality assessment

## Phase 3: Advanced Survival and Prognostic Analysis (Months 9-12)

### ‚è±Ô∏è **5. Image Biomarker Survival Analysis** (`imagebiomarkers`)
**Target Packages**: `survminer`, `maxstat`, `timeROC`

#### New Functions:
- **biomarker_cutpoint.b.R**
  - Maximally selected rank statistics
  - X-tile analysis for optimal cutpoints
  - Multiple testing correction for cutpoint selection
  - Time-dependent ROC for biomarker evaluation

- **spatial_survival.b.R**
  - Spatial feature integration with Cox models
  - Immune contexture survival analysis
  - Multi-marker prognostic signatures
  - Landmark analysis for image features

**Applications**:
- TIL density cutpoint optimization
- Spatial immune signature prognostication
- Multi-parametric biomarker panels

## Phase 4: Agreement and Reproducibility (Months 13-16)

### ü§ù **6. Digital Pathology Agreement Analysis** (`pathologyagreement`)
**Target Packages**: `irr`, `psych`, `blandr`, `irrCAC`

#### New Functions:
- **digital_agreement.b.R**
  - Multi-rater kappa (Fleiss, Light's kappa)
  - Weighted kappa for ordinal scores
  - Gwet's AC1 for paradox-resistant agreement
  - Krippendorff's alpha for various data types

- **measurement_agreement.b.R**
  - Bland-Altman plots with statistical tests
  - ICC for continuous measurements
  - Concordance correlation coefficient (CCC)
  - Total deviation index (TDI)

**Applications**:
- Algorithm vs. pathologist agreement
- Inter-observer reproducibility
- Multi-institutional validation studies

## Phase 5: Specialized Digital Pathology Methods (Months 17-20)

### üî¨ **7. Quantitative Feature Analysis** (`quantfeatures`)
**Note**: Requires pre-extracted tabular features from digital pathology

#### New Functions:
- **morphometry_stats.b.R**
  - Statistical analysis of pre-extracted nuclear measurements
  - Distribution analysis of shape features (area, perimeter, circularity)
  - Comparison of morphometric features between groups
  - Correlation with clinical outcomes

**Applications**:
- Analysis of exported morphometric data
- Statistical comparison of quantitative features
- Biomarker development from tabular measurements

### üìä **8. Multiplexed Data Statistical Analysis** (`multiplexstats`)
**Note**: Works with pre-extracted quantitative data from multiplex assays

#### New Functions:
- **multiplex_tabular.b.R**
  - Statistical analysis of marker expression levels (tabular format)
  - Correlation analysis between multiple markers
  - Phenotype frequency statistics
  - Co-expression pattern analysis

**Data Requirements**:
- Tabular data with marker intensities per cell/ROI
- Pre-processed expression matrices
- Phenotype assignments in categorical columns

## Phase 6: Integration and Validation (Months 21-24)

### üéØ **9. Statistical Analysis Pipeline for Digital Pathology Data** (`dpstatspipeline`)

#### Integration Functions:
- **tabular_workflow.b.R**
  - Import and validate tabular pathology data
  - Automated statistical analysis workflow
  - Batch processing for multiple datasets
  - Quality control of tabular inputs
  - Report generation with statistical results

### üìã **10. Clinical Translation Tools** (`clinicaltranslation`)

#### New Functions:
- **clinical_calculator.b.R**
  - Risk score calculators from image features
  - Nomogram generation for clinical use
  - Decision curve analysis
  - Clinical impact assessment

## Implementation Specifications

### New Module Structure:
```
jamovi/
‚îú‚îÄ‚îÄ spatialpathology.a.yaml
‚îú‚îÄ‚îÄ hierarchicalpathology.a.yaml
‚îú‚îÄ‚îÄ diagnosticmeta.a.yaml
‚îú‚îÄ‚îÄ mlpathology.a.yaml
‚îú‚îÄ‚îÄ imagebiomarkers.a.yaml
‚îú‚îÄ‚îÄ pathologyagreement.a.yaml
‚îú‚îÄ‚îÄ morphometry.a.yaml
‚îú‚îÄ‚îÄ multiplexpathology.a.yaml
‚îî‚îÄ‚îÄ digitalpathologypipeline.a.yaml

R/
‚îú‚îÄ‚îÄ spatialpatterns.b.R
‚îú‚îÄ‚îÄ multitype_spatial.b.R
‚îú‚îÄ‚îÄ roi_hierarchical.b.R
‚îú‚îÄ‚îÄ pathology_meta.b.R
‚îú‚îÄ‚îÄ classification_metrics.b.R
‚îú‚îÄ‚îÄ segmentation_metrics.b.R
‚îú‚îÄ‚îÄ biomarker_cutpoint.b.R
‚îú‚îÄ‚îÄ spatial_survival.b.R
‚îú‚îÄ‚îÄ digital_agreement.b.R
‚îú‚îÄ‚îÄ measurement_agreement.b.R
‚îú‚îÄ‚îÄ texture_analysis.b.R
‚îú‚îÄ‚îÄ nuclear_morphometry.b.R
‚îú‚îÄ‚îÄ multiplex_analysis.b.R
‚îú‚îÄ‚îÄ pipeline_integration.b.R
‚îî‚îÄ‚îÄ clinical_calculator.b.R
```

### Dependencies to Add:
```r
Imports:
  spatstat,
  spatialTIME,
  mada,
  irr,
  irrCAC,
  blandr,
  maxstat,
  timeROC,
  MLmetrics
  
Suggests:
  SpatialQPFs,
  EBImage,
  radiomics,
  phenoptr
```

## Priority Implementation Order

### Immediate (Months 1-6):
1. **Spatial Point Pattern Analysis** - Essential for immune profiling
2. **Classification Performance Metrics** - Critical for AI validation
3. **ROI Hierarchical Analysis** - Addresses multi-level data structure

### High Priority (Months 7-12):
4. **Image Biomarker Survival Analysis** - Clinical translation
5. **Digital Agreement Analysis** - Validation studies
6. **Diagnostic Meta-Analysis** - Evidence synthesis

### Medium Priority (Months 13-18):
7. **Texture and Morphometry Analysis** - Advanced features
8. **Multiplexed Imaging Analysis** - Emerging technologies

### Future Enhancement (Months 19-24):
9. **Comprehensive Pipeline** - Workflow automation
10. **Clinical Translation Tools** - Point-of-care integration

## Expected Impact

### Research Quality:
- **80% reduction** in spatial analysis errors through proper statistical methods
- **Standardized validation** metrics for AI algorithms
- **Robust multi-level analysis** for WSI studies

### Clinical Translation:
- **Validated biomarker cutpoints** for clinical decision-making
- **Reproducible spatial signatures** for patient stratification
- **Evidence-based algorithm deployment** in clinical practice

### User Adoption Metrics:
- Target: **500+ digital pathology labs** within 2 years
- Expected: **100+ publications** citing these methods
- Goal: **Industry standard** for digital pathology statistics

## Success Criteria

1. **Method Validation**: Each method validated against published benchmarks
2. **Performance**: Processing 1000+ ROIs in <5 minutes
3. **Usability**: GUI-based interface requiring no coding
4. **Documentation**: Comprehensive tutorials with pathology examples
5. **Integration**: Seamless workflow with existing ClinicoPath modules

This implementation will establish ClinicoPath as the premier statistical analysis platform for digital pathology research, bridging the gap between image analysis and clinical interpretation.

---

# Enhanced Digital Pathology Statistical Methods - Gemini Analysis Integration

## Executive Summary

Based on the comprehensive Gemini analysis of digital pathology workflows and statistical methods, this enhanced roadmap adds critical components for handling the complete digital pathology pipeline from WSI generation to clinical insights. The analysis emphasizes the importance of quality control, batch effect detection, and proper statistical assumptions checking throughout the entire workflow.

## New Priority Areas from Gemini Analysis

### üö® **Critical Addition: Data Quality and Batch Effect Control for Tabular Data**

#### **Quality Control for Pathology Tables** (`tabularqc`)
**Priority**: IMMEDIATE - Must be implemented before any statistical analysis

**New Functions**:
- **batch_effect_tabular.b.R**
  - PCA visualization of tabular features by batch variables
  - Statistical comparison across technical groups (scanner_ID, batch_ID)
  - Batch effect quantification in feature matrices
  - ComBat batch correction for tabular data

- **feature_quality_check.b.R**
  - Distribution analysis of quantitative features
  - Missing data pattern detection
  - Outlier detection in measurements
  - Feature correlation and redundancy analysis

**Data Format**: Tabular data with technical metadata columns

### üìä **Enhanced Foundational Statistics Suite**

#### **Advanced Descriptive Statistics** (`enhanceddescriptive`)

Based on Gemini's emphasis on proper exploratory data analysis:

- **feature_exploration.b.R**
  - Automatic generation of "Table 1" for pathology studies
  - Multi-level descriptive statistics (cell, ROI, slide, patient)
  - Feature correlation matrices with significance testing
  - Bimodality detection for identifying distinct cell populations

#### **Assumption-Aware Testing** (`assumptionaware`)

- **parametric_assumptions.b.R**
  - Automatic assumption checking before t-tests/ANOVA
  - Variance homogeneity testing (Levene's, Brown-Forsythe)
  - Normality assessment with effect size reporting
  - Automatic fallback to non-parametric alternatives

### üî¨ **Advanced Spatial Statistics Framework**

Building on Gemini's comprehensive spatial analysis hierarchy:

#### **Hierarchical Spatial Questions** (`spatialhierarchy`)

**Density Analysis from Coordinates**:
- **coordinate_density.b.R**
  - Cell density calculations from X,Y coordinate tables
  - Statistical comparison of densities between regions
  - Export density metrics as tabular summaries

**Distance-Based Analysis**:
- **distance_statistics.b.R**
  - Pairwise distance calculations from coordinate tables
  - Statistical analysis of nearest neighbor distances
  - Distance-based clustering validation

**Neighborhood Analysis from Tables**:
- **neighborhood_stats.b.R**
  - Statistical analysis of pre-computed neighborhood compositions
  - Frequency analysis of cell type combinations
  - Chi-square tests for spatial associations

### üéØ **Comprehensive Survival Analysis Enhancement**

Per Gemini's detailed survival analysis requirements:

#### **Advanced Kaplan-Meier Features** (`enhancedkm`)
- **optimal_dichotomization.b.R**
  - Median-based stratification
  - Quartile-based multi-group analysis
  - Data-driven cutpoint selection with validation
  - Risk table integration with confidence intervals

#### **Cox Model Diagnostics** (`coxdiagnostics`)
- **proportional_hazards_check.b.R**
  - Schoenfeld residuals analysis
  - Time-varying coefficient detection
  - Martingale residual plots
  - Influence diagnostics for outlier detection

### üìà **Publication-Ready Output Framework**

Following Gemini's emphasis on user-friendly, publication-quality outputs:

#### **Natural Language Results** (`nlresults`)
- **statistical_interpretation.b.R**
  - Automatic generation of methods sections
  - Plain-language result summaries
  - Effect size interpretation guidelines
  - Clinical significance vs. statistical significance

#### **Visualization Excellence** (`publicationplots`)
- **ggplot2_templates.b.R**
  - Journal-specific formatting templates
  - Colorblind-friendly palettes
  - High-resolution export options
  - Interactive plot generation for supplementary materials

## Enhanced Implementation Roadmap

### Phase 0: Foundation (Month 0-1) - NEW CRITICAL PHASE

**Quality Control Implementation**:
1. Batch effect detection framework
2. Data quality assessment pipeline
3. Technical artifact identification
4. Standardization protocols

**Rationale**: Gemini analysis shows that "garbage in, garbage out" is the primary threat to valid statistical conclusions in digital pathology.

### Phase 1: Core Statistics with Assumptions (Months 1-4)

**Enhanced Classical Tests**:
- All tests include automatic assumption checking
- Transparent reporting of assumption violations
- Guided selection between parametric/non-parametric methods
- Effect size reporting for all comparisons

### Phase 2: Spatial Analysis Hierarchy (Months 5-8)

**Three-Tier Spatial Framework**:
1. **Where** (First-order): Density and intensity patterns
2. **How** (Second-order): Clustering and dispersion
3. **With Whom** (Multi-type): Cellular neighborhoods and niches

### Phase 3: Model-Based Analysis (Months 9-12)

**Regression Framework**:
- Linear models with diagnostic plots
- Logistic regression with calibration assessment
- Poisson/Negative Binomial for count data
- Zero-inflated models for sparse data

### Phase 4: Advanced Methods (Months 13-16)

**Machine Learning Integration**:
- Random Forest with interpretability
- Gradient boosting with SHAP values
- Deep learning integration hooks
- Cross-validation strategies for pathology data

### Phase 5: Clinical Translation (Months 17-20)

**Clinical Decision Support**:
- Risk calculators with confidence intervals
- Nomogram generation
- Decision curve analysis
- Cost-effectiveness integration

## Technical Implementation Details

### Enhanced R Package Dependencies

```r
# Core Statistical Packages
Imports:
  # Quality Control
  performance,    # Model diagnostics
  datawizard,    # Data exploration
  see,           # Visualization grammar
  
  # Spatial Analysis
  spatstat.explore,  # Modern spatstat
  spatstat.model,    # Model fitting
  SpatialQPFs,      # Pathology-specific
  
  # Publication Quality
  gtsummary,     # Table 1 generation
  ggpubr,        # Publication plots
  patchwork,     # Plot composition
  
  # Natural Language
  report,        # Automated reporting
  
# Suggested Packages  
Suggests:
  # Advanced Spatial
  spatialTIME,
  phenoptr,
  
  # Machine Learning
  tidymodels,    # Unified ML framework
  DALEX,         # Model explanations
```

### Module Architecture Enhancement

```yaml
# New module structure
jamovi/
‚îú‚îÄ‚îÄ qualitycontrol/
‚îÇ   ‚îú‚îÄ‚îÄ batcheffect.a.yaml
‚îÇ   ‚îú‚îÄ‚îÄ dataquality.a.yaml
‚îÇ   ‚îî‚îÄ‚îÄ technicalqc.a.yaml
‚îú‚îÄ‚îÄ spatialanalysis/
‚îÇ   ‚îú‚îÄ‚îÄ firstorder.a.yaml
‚îÇ   ‚îú‚îÄ‚îÄ secondorder.a.yaml
‚îÇ   ‚îî‚îÄ‚îÄ multitype.a.yaml
‚îú‚îÄ‚îÄ assumptions/
‚îÇ   ‚îú‚îÄ‚îÄ normality.a.yaml
‚îÇ   ‚îú‚îÄ‚îÄ variance.a.yaml
‚îÇ   ‚îî‚îÄ‚îÄ independence.a.yaml
‚îî‚îÄ‚îÄ reporting/
    ‚îú‚îÄ‚îÄ naturallanguage.a.yaml
    ‚îî‚îÄ‚îÄ publication.a.yaml
```

## Key Innovations from Gemini Analysis

### 1. **Holistic Pipeline Awareness**
- Every analysis includes upstream quality checks
- Batch effect assessment is mandatory, not optional
- Technical metadata tracking throughout analysis

### 2. **Hierarchical Spatial Framework**
- Structured progression from simple to complex spatial questions
- Biologically interpretable parameters (e.g., Thomas process)
- Integration with modern graph-based methods

### 3. **User-Centric Design**
- Natural language summaries for all analyses
- Guided decision-making for test selection
- Publication-ready outputs by default

### 4. **Reproducibility Focus**
- Comprehensive logging of all decisions
- Seed management for stochastic methods
- Version tracking for all dependencies

## Expected Outcomes

### Immediate Impact (Months 1-6):
- **90% reduction** in batch effect-related false discoveries
- **Complete assumption checking** for all statistical tests
- **Standardized quality control** across all digital pathology studies

### Medium-term Impact (Months 7-12):
- **Hierarchical spatial analysis** becoming standard practice
- **Model-based clustering** replacing arbitrary cutpoints
- **Graph-based niche discovery** for complex tissue architecture

### Long-term Impact (Months 13-20):
- **Fully integrated pipeline** from WSI to publication
- **Natural language reporting** reducing interpretation errors
- **Clinical decision tools** directly from pathology images

## Success Metrics

1. **Quality Assurance**: 100% of analyses include batch effect assessment
2. **Statistical Rigor**: Zero assumption violations go unreported
3. **Spatial Completeness**: All three spatial hierarchy levels available
4. **User Satisfaction**: 95% can generate publication-ready results
5. **Clinical Adoption**: 50+ clinical labs using the module within 2 years

## Conclusion

The Gemini analysis reveals that successful digital pathology statistics requires more than just implementing tests‚Äîit demands a comprehensive framework that acknowledges the entire data generation pipeline, enforces quality control, and guides users through appropriate statistical choices. This enhanced roadmap positions ClinicoPath not just as a statistical tool, but as a complete analytical ecosystem for digital pathology research.

---

# Comprehensive Anatomic Pathology Statistical Framework - Complete Coverage Plan

## Vision Statement

Transform ClinicoPath into the definitive statistical analysis platform for ALL anatomic pathology research, providing specialized tools for every subspecialty while maintaining a unified, user-friendly interface that empowers pathologists to conduct rigorous, reproducible research across all domains of their practice.

## Part I: Subspecialty-Specific Statistical Modules

### üß† **1. Neuropathology Module** (`neuropath`)

#### Specialized Statistical Methods:
- **brain_tumor_grading.b.R**
  - WHO grade progression analysis
  - IDH mutation status correlation
  - MGMT methylation survival analysis
  - Molecular subtype clustering (GBM, oligodendroglioma, etc.)

- **neurodegenerative_staging.b.R**
  - Braak & Braak staging statistics
  - CERAD score analysis
  - Tau/amyloid burden quantification
  - Regional brain analysis with multiple comparison correction

- **pediatric_brain_analysis.b.R**
  - Medulloblastoma molecular subgrouping
  - H3K27M mutation impact analysis
  - Age-adjusted survival models

**Unique Statistical Needs**:
- Spatial analysis for regional brain involvement
- Hierarchical models for multi-region sampling
- Time-to-progression analysis for grade transformation

### ü´Å **2. Pulmonary Pathology Module** (`pulmpath`)

#### Specialized Methods:
- **lung_cancer_staging.b.R**
  - TNM stage migration analysis
  - PD-L1 TPS score optimization
  - Tumor mutation burden correlation
  - Spread through air spaces (STAS) analysis

- **interstitial_disease_scoring.b.R**
  - UIP pattern recognition statistics
  - Fibrosis score progression modeling
  - Multi-lobe sampling variance analysis
  - Ashcroft score reliability metrics

- **mesothelioma_diagnosis.b.R**
  - BAP1/MTAP loss correlation
  - Calretinin/WT1 diagnostic accuracy
  - Asbestos burden quantification

**Unique Needs**:
- Multi-site biopsy concordance analysis
- Spatial heterogeneity in large resections
- Molecular-morphologic correlation statistics

### ü©∏ **3. Hematopathology Module** (`hematopath`)

#### Specialized Methods:
- **lymphoma_classification.b.R**
  - Hans algorithm statistics
  - Cell-of-origin classification
  - MYC/BCL2/BCL6 rearrangement analysis
  - Ki-67 proliferation index optimization

- **flow_cytometry_integration.b.R**
  - Flow-morphology correlation
  - Minimal residual disease (MRD) detection
  - Immunophenotype clustering
  - Aberrant antigen expression analysis

- **bone_marrow_analysis.b.R**
  - Cellularity age-adjustment
  - M:E ratio calculation
  - Blast count optimization
  - Fibrosis grading statistics

**Unique Needs**:
- Multi-parameter flow cytometry analysis
- Clonality assessment statistics
- Sequential biopsy comparison methods

### ü¶¥ **4. Bone and Soft Tissue Pathology Module** (`softissue`)

#### Specialized Methods:
- **sarcoma_grading.b.R**
  - FNCLCC grading system analysis
  - Mitotic count standardization
  - Necrosis percentage estimation
  - Molecular subtype correlation

- **margin_assessment.b.R**
  - R0/R1/R2 classification statistics
  - Distance to margin optimization
  - Multi-focal tumor analysis
  - Re-excision prediction models

- **bone_tumor_analysis.b.R**
  - Enneking staging statistics
  - Growth rate modeling
  - Response to neoadjuvant therapy
  - Pathological fracture risk assessment

**Unique Needs**:
- 3D margin assessment statistics
- Heterogeneous tumor sampling
- Treatment effect quantification

### üß¨ **5. Molecular Pathology Integration Module** (`molpath`)

#### Specialized Methods:
- **ngs_integration.b.R**
  - Variant allele frequency (VAF) analysis
  - Tumor mutational burden (TMB) statistics
  - Microsatellite instability (MSI) scoring
  - Clonal evolution modeling

- **fish_analysis.b.R**
  - HER2/CEP17 ratio optimization
  - ALK/ROS1 rearrangement statistics
  - Amplification vs. polysomy discrimination
  - Cut-off optimization for novel probes

- **methylation_profiling.b.R**
  - CpG island methylator phenotype (CIMP)
  - Methylation age calculation
  - Tumor classification by methylation
  - Prognostic methylation signatures

**Unique Needs**:
- Multi-platform data integration
- Variant interpretation statistics
- Germline vs. somatic discrimination

### üë∂ **6. Pediatric Pathology Module** (`pedpath`)

#### Specialized Methods:
- **developmental_staging.b.R**
  - Gestational age adjustment
  - Growth curve integration
  - Maturation assessment statistics
  - Congenital anomaly clustering

- **pediatric_tumors.b.R**
  - Age-specific incidence modeling
  - International Neuroblastoma criteria
  - Wilms tumor staging statistics
  - Risk stratification models

- **placental_pathology.b.R**
  - Villous maturation scoring
  - Maternal vascular malperfusion
  - Fetal vascular malperfusion
  - Twin-twin transfusion analysis

**Unique Needs**:
- Age-adjusted normal ranges
- Growth-adjusted statistics
- Developmental stage correlation

### üî¨ **7. Cytopathology Module** (`cytopath`)

#### Specialized Methods:
- **bethesda_analysis.b.R**
  - Bethesda system statistics (thyroid, cervical)
  - ROM (Risk of Malignancy) calculation
  - Adequacy assessment metrics
  - Inter-observer variability in categories

- **liquid_based_cytology.b.R**
  - HPV co-testing integration
  - Cell block correlation
  - Atypical cell quantification
  - Screening error analysis

- **fine_needle_aspiration.b.R**
  - Milan system statistics (salivary)
  - Paris system (urinary)
  - IAC system (pancreatobiliary)
  - Rapid on-site evaluation (ROSE) accuracy

**Unique Needs**:
- Sample adequacy statistics
- Screening sensitivity/specificity
- Cyto-histologic correlation

### üè• **8. Transplant Pathology Module** (`transplant`)

#### Specialized Methods:
- **rejection_scoring.b.R**
  - Banff classification statistics
  - C4d deposition quantification
  - DSA correlation analysis
  - Time-to-rejection modeling

- **graft_survival_analysis.b.R**
  - Competing risks (rejection vs. infection)
  - Recurrent disease modeling
  - Protocol vs. indication biopsy analysis
  - Multi-state transition models

- **immunosuppression_effects.b.R**
  - Drug toxicity scoring
  - Opportunistic infection rates
  - PTLD risk assessment
  - Calcineurin inhibitor toxicity

**Unique Needs**:
- Longitudinal biopsy analysis
- Time-varying covariate models
- Multi-organ correlation statistics

### üß™ **9. Gastrointestinal Pathology Module** (`gipath`)

#### Specialized Methods:
- **ibd_scoring.b.R**
  - Nancy index, Robarts index
  - Geboes score analysis
  - Activity vs. chronicity discrimination
  - Dysplasia detection statistics

- **barrett_surveillance.b.R**
  - Prague classification
  - Dysplasia progression modeling
  - Sampling error correction
  - Risk stratification algorithms

- **polyp_analysis.b.R**
  - Advanced adenoma criteria
  - Serrated pathway statistics
  - Size measurement standardization
  - Surveillance interval optimization

**Unique Needs**:
- Multi-level sampling statistics
- Longitudinal surveillance analysis
- Field effect quantification

### üíÄ **10. Autopsy Pathology Module** (`autopsy`)

#### Specialized Methods:
- **cause_of_death_analysis.b.R**
  - Primary vs. contributory cause statistics
  - Multi-organ failure modeling
  - Sudden death classification
  - Discrepancy rate analysis

- **postmortem_interval.b.R**
  - Decomposition stage modeling
  - Time since death estimation
  - Artifact vs. pathology discrimination
  - Toxicology correlation

- **clinical_correlation.b.R**
  - Ante-mortem vs. post-mortem diagnosis
  - Missed diagnosis analysis
  - Quality assurance metrics
  - Learning value assessment

**Unique Needs**:
- Multi-organ correlation analysis
- Temporal sequence modeling
- Artifact adjustment statistics

## Part II: Cross-Cutting Analytical Frameworks

### üìä **A. Universal Pathology Statistics Core** (`pathcore`)

#### Essential Methods for All Subspecialties:
- **specimen_adequacy.b.R**
  - Sample size calculations
  - Adequacy criteria by specimen type
  - Quality metrics dashboard
  - Turnaround time analysis

- **diagnostic_concordance.b.R**
  - Second opinion agreement
  - Expert panel consensus
  - Frozen-permanent concordance
  - Intradepartmental consultation patterns

- **quality_assurance.b.R**
  - Amendment/correction rates
  - Critical value reporting
  - CAP checklist compliance
  - Peer review statistics

### üéØ **B. Biomarker Development Framework** (`biomarkerdev`)

#### Comprehensive Biomarker Pipeline:
- **discovery_phase.b.R**
  - High-throughput screening statistics
  - Multiple testing correction
  - Feature selection algorithms
  - Preliminary cutpoint determination

- **validation_phase.b.R**
  - Independent cohort validation
  - Multi-institutional reproducibility
  - Pre-analytical variable assessment
  - Clinical utility metrics

- **implementation_phase.b.R**
  - Laboratory developed test (LDT) validation
  - Proficiency testing analysis
  - External quality assessment
  - Real-world performance monitoring

### ü§ñ **C. AI/ML Integration Framework** (`aipath`)

#### Machine Learning for Pathology:
- **wsi_analysis.b.R**
  - Patch-level classification aggregation
  - Attention heatmap statistics
  - Model uncertainty quantification
  - Human-AI concordance metrics

- **feature_extraction.b.R**
  - Deep feature statistical analysis
  - Handcrafted vs. learned features
  - Multi-scale feature integration
  - Interpretability metrics

- **clinical_deployment.b.R**
  - Model drift detection
  - Performance monitoring statistics
  - Fairness and bias assessment
  - Regulatory compliance metrics

## Part III: Implementation Strategy

### Phase 1: Foundation (Months 1-6)
1. **Core Infrastructure**
   - Universal pathology statistics core
   - Quality control framework
   - Basic subspecialty modules

### Phase 2: Subspecialty Development (Months 7-18)
2. **Priority Subspecialties**
   - Breast pathology (high volume)
   - GI pathology (screening programs)
   - Dermatopathology (visual analysis)
   - Hematopathology (multi-parameter)

### Phase 3: Advanced Integration (Months 19-24)
3. **Complex Modules**
   - Molecular pathology integration
   - AI/ML framework
   - Transplant pathology
   - Pediatric pathology

### Phase 4: Specialized Applications (Months 25-30)
4. **Niche Areas**
   - Autopsy pathology
   - Forensic applications
   - Veterinary pathology adaptation
   - Research-specific tools

## Part IV: Technical Architecture

### Module Organization Structure:
```
ClinicoPath/
‚îú‚îÄ‚îÄ core/
‚îÇ   ‚îú‚îÄ‚îÄ universal_stats/
‚îÇ   ‚îú‚îÄ‚îÄ quality_control/
‚îÇ   ‚îî‚îÄ‚îÄ data_management/
‚îú‚îÄ‚îÄ subspecialties/
‚îÇ   ‚îú‚îÄ‚îÄ neuropath/
‚îÇ   ‚îú‚îÄ‚îÄ pulmpath/
‚îÇ   ‚îú‚îÄ‚îÄ hematopath/
‚îÇ   ‚îú‚îÄ‚îÄ softissue/
‚îÇ   ‚îú‚îÄ‚îÄ molpath/
‚îÇ   ‚îú‚îÄ‚îÄ pedpath/
‚îÇ   ‚îú‚îÄ‚îÄ cytopath/
‚îÇ   ‚îú‚îÄ‚îÄ transplant/
‚îÇ   ‚îú‚îÄ‚îÄ gipath/
‚îÇ   ‚îî‚îÄ‚îÄ autopsy/
‚îú‚îÄ‚îÄ frameworks/
‚îÇ   ‚îú‚îÄ‚îÄ biomarker_development/
‚îÇ   ‚îú‚îÄ‚îÄ ai_integration/
‚îÇ   ‚îî‚îÄ‚îÄ clinical_trials/
‚îî‚îÄ‚îÄ integration/
    ‚îú‚îÄ‚îÄ lis_connectivity/
    ‚îú‚îÄ‚îÄ image_management/
    ‚îî‚îÄ‚îÄ reporting_tools/
```

### Key R Package Dependencies by Domain:

```r
# Subspecialty-Specific Packages
neuropath_packages <- c(
  "neurobase",      # Neuroimaging analysis
  "ANTsR",          # Advanced brain registration
  "freesurfer"      # Brain region analysis
)

hematopath_packages <- c(
  "flowCore",       # Flow cytometry analysis
  "FlowSOM",        # Flow data clustering
  "CytoML"          # Cytometry markup language
)

molpath_packages <- c(
  "GenomicRanges",  # Genomic interval analysis
  "VariantAnnotation", # Variant analysis
  "methylKit"       # Methylation analysis
)

transplant_packages <- c(
  "transplantr",    # Transplant-specific stats
  "competing risks", # Graft survival analysis
  "DSA"             # Donor-specific antibodies
)
```

## Part V: Expected Impact and Success Metrics

### Clinical Impact Goals:
1. **Coverage**: 100% of anatomic pathology subspecialties
2. **Adoption**: 500+ pathology departments globally
3. **Publications**: 1000+ papers using the module
4. **Education**: Integration into residency training
5. **Standardization**: Become CAP/ASCP recommended tool

### Quality Metrics:
- **Accuracy**: Validated against gold standard methods
- **Efficiency**: 75% reduction in analysis time
- **Reproducibility**: 100% result reproducibility
- **Accessibility**: No coding required for 95% of analyses
- **Compliance**: Meets all regulatory requirements

### Innovation Metrics:
- **Novel Methods**: 50+ pathology-specific statistical methods
- **AI Integration**: Seamless ML model deployment
- **Real-time Analysis**: Sub-second response for routine analyses
- **Cloud Scalability**: Handle institutional-scale data
- **Interoperability**: LIS/PACS integration

## Part VI: Sustainability and Growth

### Community Development:
1. **Open Source Governance**: Establish steering committee
2. **Contribution Guidelines**: Enable community modules
3. **Plugin Architecture**: Allow third-party extensions
4. **Educational Resources**: Comprehensive documentation
5. **Support Network**: User forums and help desk

### Funding Strategy:
1. **Research Grants**: NIH/NSF pathology informatics
2. **Industry Partnerships**: Diagnostic companies
3. **Institutional Licenses**: Enterprise deployments
4. **Training Programs**: Certification courses
5. **Consulting Services**: Custom implementations

### Future Directions:
1. **Digital Twins**: Patient-specific modeling
2. **Federated Learning**: Multi-institutional AI
3. **Real-time Decisions**: Intraoperative consultation
4. **Predictive Pathology**: Outcome forecasting
5. **Precision Medicine**: Treatment selection algorithms

## Conclusion

This comprehensive plan transforms ClinicoPath from a statistical tool into the definitive platform for anatomic pathology research. By providing specialized methods for every subspecialty while maintaining a unified framework, we empower pathologists to conduct rigorous, reproducible research that directly impacts patient care. The modular architecture ensures scalability, the open-source approach fosters innovation, and the focus on user experience removes barriers to advanced statistical analysis.

The ultimate goal: Every pathologist, regardless of statistical expertise, can perform publication-quality analyses that advance the field and improve patient outcomes.



# üéØ ClinicoPath Survival Analysis Enhancement Roadmap

## Status Overview (Updated: January 2025)

### ‚úÖ **Already Implemented** (Current Session)

1. **Enhanced Competing Risks** (`competingsurvival.b.R`) - Gray's test, Fine-Gray models
2. **Cure Models** (`curemodels.b.R`) - Mixture/non-mixture models for long-term survivors  
3. **Multistate Models** (`multistatesurvival.b.R`) - Disease progression tracking
4. **Machine Learning Survival** (Enhanced `multisurvival.a.yaml`) - RSF, XGBoost, SHAP, ensemble methods
5. **Relative Survival** (`relativesurvival.b.R`) - Population-based survival comparison

### üöÄ **Implementation Queue: High-Impact Features** (Priority Order)

#### **Phase 1: Core Validation & Modeling (Next 2 months)**

##### **1. Advanced Model Validation Suite** (`pec`, `timeROC`, `survAUC`)

```yaml
Module: survivalvalidation.a.yaml / survivalvalidation.b.R
Priority: üî• Critical
Dependencies: pec, timeROC, survAUC, riskRegression

Key Features:
- Prediction Error Curves (PEC)
- Time-dependent ROC/AUC curves
- Integrated Brier Score (IBS)
- Calibration plots with slopes/intercepts
- Cross-validated Concordance Index
- Decision curve analysis
- Bootstrap validation
- Apparent vs optimism-corrected performance

Clinical Impact:
- Essential quality assurance for all survival models
- Model comparison and selection
- Publication-ready validation metrics
- Regulatory compliance (FDA, EMA)
```

##### **2. Joint Longitudinal-Survival Models** (`JMbayes2`, `joineR`)

```yaml
Module: jointmodeling.a.yaml / jointmodeling.b.R
Priority: üî• Critical
Dependencies: JMbayes2, joineR, rstanarm, nlme

Key Features:
- Link repeated biomarker measurements to survival
- Dynamic risk prediction updates
- Individual-specific survival trajectories
- Time-varying biomarker effects
- Bayesian joint modeling framework
- Multi-marker joint models
- Dynamic discrimination indices

Clinical Impact:
- Personalized medicine applications
- Dynamic biomarker utilization
- Precision oncology
- Treatment monitoring
```

##### **3. Time-Dependent Covariates & ROC** (`timeROC`, `pROC`, `plotROC`)

```yaml
Module: timedependent.a.yaml / timedependent.b.R
Priority: üî• High  
Dependencies: timeROC, pROC, plotROC, survival

Key Features:
- Time-varying coefficient models
- Landmark analysis framework
- Dynamic AUC curves over time
- Optimal cutpoint selection over time
- Time-dependent associations
- Schoenfeld residuals analysis
- Time-stratified models

Clinical Impact:
- Dynamic prediction capabilities
- Screening program optimization
- Time-varying treatment effects
- Adaptive clinical decision making
```

#### **Phase 2: Specialized Models (Months 3-4)**

##### **4. Frailty & Random Effects Models** (`coxme`, `frailtypack`, `parfm`)

```yaml
Module: frailtymodels.a.yaml / frailtymodels.b.R
Priority: ‚ö° High
Dependencies: coxme, frailtypack, parfm, survival

Key Features:
- Shared frailty models (gamma, lognormal)
- Correlated frailty for family studies
- Random effects for clustering
- Multi-level survival models
- Center effects in multicenter trials
- Spatial frailty models
- Nested frailty structures

Clinical Impact:
- Multi-center clinical trials
- Family-based genetic studies
- Geographic health disparities
- Institutional quality assessment
```

##### **5. Pseudo-Observations Methods** (`pseudo`, `geepack`)

```yaml
Module: pseudoobs.a.yaml / pseudoobs.b.R
Priority: ‚ö° Medium
Dependencies: pseudo, geepack, prodlim

Key Features:
- Pseudo-values for survival probability
- Restricted Mean Survival Time (RMST) regression
- Cumulative incidence regression
- GEE models for survival outcomes
- Direct covariate effects on survival probability
- Flexible modeling of survival curves

Clinical Impact:
- Alternative to Cox proportional hazards
- Direct interpretation of survival probability
- Robust inference for clustered data
- Flexible survival curve modeling
```

##### **6. Interval-Censored Survival** (`icenReg`, `interval`, `survPresmooth`)

```yaml
Module: intervalcensored.a.yaml / intervalcensored.b.R
Priority: ‚ö° Medium
Dependencies: icenReg, interval, survPresmooth, Icens

Key Features:
- Turnbull estimator (NPMLE)
- Parametric interval-censored models
- Semi-parametric approaches
- Smoothed survival curve estimation
- Regression models for interval-censored data
- Goodness of fit tests

Clinical Impact:
- Real-world data analysis
- Screening studies (time to detection)
- Disease onset modeling
- Laboratory test intervals
```

#### **Phase 3: Advanced Clinical Applications (Months 5-6)**

##### **7. Recurrent Event Analysis** (`reda`, `reReg`, `survrec`)

```yaml
Module: recurrentevents.a.yaml / recurrentevents.b.R
Priority: ‚ú® Medium
Dependencies: reda, reReg, survrec, frailtypack

Key Features:
- Andersen-Gill counting process models
- Prentice-Williams-Peterson models
- Frailty models for recurrent events
- Mean cumulative function (MCF)
- Gap time vs calendar time models
- Terminal event modeling

Clinical Impact:
- Cancer recurrence studies
- Chronic disease exacerbations
- Hospital readmissions
- Infection recurrences
```

##### **8. Advanced Biomarker Integration** (`survcomp`, `Biomarker`)

```yaml
Module: biomarkersurvival.a.yaml / biomarkersurvival.b.R
Priority: ‚ú® Medium
Dependencies: survcomp, Biomarker, OptimalCutpoints

Key Features:
- Biomarker cut-point optimization
- Time-dependent biomarker modeling
- Multiple biomarker integration
- Predictive vs prognostic analysis
- Biomarker signature development
- Cross-validation for biomarkers

Clinical Impact:
- Precision medicine
- Companion diagnostics
- Treatment selection
- Prognostic tool development
```

#### **Phase 4: Research & Specialized Methods (Future)**

##### **9. Bayesian Survival Analysis** (`rstanarm`, `brms`, `INLA`)

```yaml
Module: bayesiansurvival.a.yaml / bayesiansurvival.b.R
Priority: ‚ú® Research
Dependencies: rstanarm, brms, INLA, rstan

Key Features:
- Bayesian Cox models
- Prior specification interfaces
- Posterior predictive checks
- MCMC diagnostics and convergence
- Bayesian model averaging
- Hierarchical survival models

Clinical Impact:
- Uncertainty quantification
- Prior knowledge incorporation
- Small sample studies
- Meta-analysis applications
```

##### **10. Causal Survival Analysis** (`CausalImpact`, `MatchIt`, `WeightIt`)

```yaml
Module: causalsurvival.a.yaml / causalsurvival.b.R
Priority: ‚ú® Research
Dependencies: CausalImpact, MatchIt, WeightIt, tmle

Key Features:
- Propensity score matching for survival
- Instrumental variable survival analysis
- G-methods (G-formula, IPW, G-estimation)
- Marginal structural models
- Targeted maximum likelihood estimation

Clinical Impact:
- Observational study causal inference
- Treatment effectiveness evaluation
- Health policy evaluation
- Real-world evidence generation
```

##### **11. Spatial Survival Models** (`spBayesSurv`, `geoR`)

```yaml
Module: spatialsurvival.a.yaml / spatialsurvival.b.R
Priority: ‚ú® Specialized
Dependencies: spBayesSurv, geoR, sp, spdep

Key Features:
- Geographic survival modeling
- Spatial clustering detection
- Environmental factor integration
- Disease mapping
- Spatial frailty models

Clinical Impact:
- Geographic health disparities
- Environmental epidemiology
- Cancer clusters investigation
- Health services research
```

